HR-Positive Metastatic Breast Cancer — An Interview with Dr Erika Hamilton on the Potential Role of PROTAC Estrogen Receptor Degraders
Breast Cancer Update
00:00
Mechanisms of endocrine resistance and AKT role
She outlines genetic resistance drivers, AKT/PI3K pathway relevance and combining AKT inhibitors with degraders.
Play episode from 10:17
Transcript
